A drug used to treat acute myeloid leukemia that has a mutated (changed) form of a gene called isocitrate dehydrogenase-1 (IDH1). It is used in adults whose cancer is newly diagnosed and who are either 75 years and older or cannot be treated with other anticancer drugs. Ivosidenib is also used in adults whose cancer has relapsed (come back) or has not gotten better after treatment with other anticancer therapy. It is also being studied in the treatment of other types of cancer. Ivosidenib blocks the protein made by the mutated IDH1 gene. Blocking this protein may help keep cancer cells from growing. Ivosidenib is a type of enzyme inhibitor and a type of targeted therapy. Also called Tibsovo.